← FDA DRUG APPROVALS

FDA ANDA · ANDA077166

VENLAFAXINE HYDROCHLORIDE

Sponsor: PHARMOBEDIENT

APPLICATION
ANDA077166
TYPE
ANDA
ORIGINAL APPROVAL
2008-06-13
LATEST ACTION
2023-08-18
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

VENLAFAXINE HYDROCHLORIDEDiscontinued
VENLAFAXINE HYDROCHLORIDE EQ 100MG BASE · TABLET · ORAL
VENLAFAXINE HYDROCHLORIDEDiscontinued
VENLAFAXINE HYDROCHLORIDE EQ 50MG BASE · TABLET · ORAL
VENLAFAXINE HYDROCHLORIDEDiscontinued
VENLAFAXINE HYDROCHLORIDE EQ 25MG BASE · TABLET · ORAL
VENLAFAXINE HYDROCHLORIDEDiscontinued
VENLAFAXINE HYDROCHLORIDE EQ 75MG BASE · TABLET · ORAL
VENLAFAXINE HYDROCHLORIDEDiscontinued
VENLAFAXINE HYDROCHLORIDE EQ 37.5MG BASE · TABLET · ORAL

Approval history

2023-08-18Labeling · Supplement 20 · standardAP
2021-09-20Labeling · Supplement 18 · standardAP
2020-04-14Labeling · Supplement 17 · standardAP
2017-01-04Labeling · Supplement 16 · standardAP
2016-02-02Labeling · Supplement 15 · standardAP
2014-07-17Labeling · Supplement 14 · standardAP
2014-07-07Labeling · Supplement 13 · standardAP
2014-07-07Labeling · Supplement 11 · standardAP
2011-01-30Manufacturing (CMC) · Supplement 8AP
2010-09-27Labeling · Supplement 7AP
2009-07-23Labeling · Supplement 1AP
2008-06-13Original — Other Important Information from FDA ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →